IL197701A - הרכב מוצק המכיל ננו–מיצלות ותהליך להכנתם - Google Patents

הרכב מוצק המכיל ננו–מיצלות ותהליך להכנתם

Info

Publication number
IL197701A
IL197701A IL197701A IL19770109A IL197701A IL 197701 A IL197701 A IL 197701A IL 197701 A IL197701 A IL 197701A IL 19770109 A IL19770109 A IL 19770109A IL 197701 A IL197701 A IL 197701A
Authority
IL
Israel
Prior art keywords
micelles
mixture
composition according
poorly soluble
water
Prior art date
Application number
IL197701A
Other languages
English (en)
Other versions
IL197701A0 (en
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Publication of IL197701A0 publication Critical patent/IL197701A0/en
Publication of IL197701A publication Critical patent/IL197701A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL197701A 2006-10-20 2009-03-19 הרכב מוצק המכיל ננו–מיצלות ותהליך להכנתם IL197701A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85302306P 2006-10-20 2006-10-20
EP06122648 2006-10-20
PCT/EP2007/061194 WO2008046905A1 (en) 2006-10-20 2007-10-19 Micellar nanoparticles of chemical substances

Publications (2)

Publication Number Publication Date
IL197701A0 IL197701A0 (en) 2009-12-24
IL197701A true IL197701A (he) 2014-12-31

Family

ID=38661928

Family Applications (1)

Application Number Title Priority Date Filing Date
IL197701A IL197701A (he) 2006-10-20 2009-03-19 הרכב מוצק המכיל ננו–מיצלות ותהליך להכנתם

Country Status (9)

Country Link
EP (1) EP2083799A1 (he)
JP (1) JP5439182B2 (he)
KR (1) KR101434334B1 (he)
AU (1) AU2007312233B2 (he)
CA (1) CA2666587C (he)
EA (1) EA026213B1 (he)
IL (1) IL197701A (he)
NO (1) NO20091975L (he)
WO (1) WO2008046905A1 (he)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071375A1 (es) 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
WO2010029374A1 (en) 2008-09-12 2010-03-18 Critical Pharmaceuticals Limited Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
WO2013163162A1 (en) * 2012-04-24 2013-10-31 Amylin Pharmaceuticals, Llc Site-specific enzymatic modification of exendins and analogs thereof
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
FR3014317B1 (fr) * 2013-12-11 2016-04-22 Patrice Binay Nouveau procede de fabrication de formulations pharmaceutiques transmuqueuses et formations ainsi obtenues
EP3424493A1 (en) 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
EP3886910A4 (en) * 2018-11-30 2022-07-27 Canopy Growth Corporation A CANNABINOID OR A CANNABIS-CONTAINING COMPOUND, PROCESS FOR THEIR PRODUCTION AND THEIR USE
US20220249370A1 (en) * 2019-07-25 2022-08-11 Beijing Shenogen Pharma Group Ltd. Nano-micelle preparation of icaritin and preparation method therefor and application thereof
CN112915121A (zh) 2019-12-06 2021-06-08 汉义生物科技（北京）有限公司 一种大麻素纳米胶束制剂及其制备方法
AU2020403651A1 (en) 2019-12-09 2022-07-07 Nicoventures Trading Limited Oral product comprising a cannabinoid
WO2023002197A1 (en) * 2021-07-22 2023-01-26 Nicoventures Trading Limited Compositions comprising a constituent, derivative or extract of cannabis
IL309702A (he) * 2021-07-22 2024-02-01 Nicoventures Trading Ltd הרכב הכולל מרכיב, נגזרת או מיצוי של קנאביס
IL309703A (he) * 2021-07-22 2024-02-01 Nicoventures Trading Ltd מרכיב, נגזרת או מיצוי של קנאביס במטריקס מסיס במים
AU2022315022A1 (en) * 2021-07-22 2024-01-18 Nicoventures Trading Limited Compositions comprising constituents, derivatives or extracts of cannabis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
AU2002333853B2 (en) * 2001-09-21 2006-07-13 Solvay Pharmaceuticals B.V. 4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
UA78523C2 (en) * 2001-09-21 2007-04-10 Solvay Pharm Bv 4,5-dihydro-1h-pyrazoie derivatives as cb1 antagonists
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
EP1706098A4 (en) * 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICELLAR SYSTEMS SUITABLE FOR THE DELIVERY OF LIPOPHILIC OR HYDROPHOBIC COMPOUNDS
US7498309B2 (en) * 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
WO2005063206A1 (en) * 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
BRPI0517434A (pt) * 2004-10-25 2008-10-07 Solvay Pharm Gmbh composições farmacêuticas compreendendo antagonistas do receptor canabinóide cb1 e abridores de canal de potássio para o tratamento de diabetes mellitus do tipo i, obesidade e estados relacionados
UA100966C2 (ru) * 2005-04-08 2013-02-25 Эбботт Леборетриз Фармацевтическая композиция на основе 2-[4-(4-хлорбензоил)фенокси]-2-метилпропионовой кислоты и ее солей
WO2006113631A2 (en) * 2005-04-18 2006-10-26 Rubicon Research Pvt. Ltd. Bioenhanced compositions

Also Published As

Publication number Publication date
CA2666587C (en) 2015-12-22
JP5439182B2 (ja) 2014-03-12
KR101434334B1 (ko) 2014-08-28
EA026213B1 (ru) 2017-03-31
CA2666587A1 (en) 2008-04-24
WO2008046905A1 (en) 2008-04-24
EA200900572A1 (ru) 2009-10-30
JP2010506886A (ja) 2010-03-04
AU2007312233A1 (en) 2008-04-24
EP2083799A1 (en) 2009-08-05
KR20090077074A (ko) 2009-07-14
NO20091975L (no) 2009-07-09
AU2007312233B2 (en) 2012-09-20
IL197701A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
CA2666587C (en) Micellar nanoparticles of chemical substances
US7923026B2 (en) Embedded micellar nanoparticles
JP7006995B2 (ja) 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法
US11839689B2 (en) Formulations of enzalutamide
Panigrahi et al. Gelucire: A versatile polymer for modified release drug delivery system
US20200330600A1 (en) Pharmaceutical composition
KR20030003500A (ko) 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
JP6666352B2 (ja) デュタステリド含有固体分散体及びこれを含む組成物
TWI392507B (zh) 包埋的膠束奈米顆粒
ES2663721T3 (es) Formulaciones de olmesartán
Lohithasu et al. A latest review on liquisolid technique as a novel Approach
Kumar et al. Solid dispersions: An approach to enhance solubility of poorly soluble drugs
Nagargoje et al. An overview on formulation and development of nanoparticulate matrix tablets for beta blockers
BR102016015553A2 (pt) Sistemas multiparticulados liquissólidos para administração oral, processo de obtenção dos mesmos e seus usos
Lalani et al. LIQUISOLID COMPACT APPROACH TO ENHANCE DISSOLUTION RATE OF POORLY SOLUBLE DRUGS: A RECENT RESEARCH REVIEW.
CN106822122B (zh) 一种替米沙坦和氨氯地平的口服药用组合物及其制备方法
WO2010082855A1 (en) Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed